Morgan Stanley Upgrades Atea Pharmaceuticals to Equal-Weight, Raises Price Target to $6.88
Morgan Stanley Upgrades Atea Pharmaceuticals to Equal-Weight, Raises Price Target to $6.88
摩根士丹利升格atea pharmaceuticals評級，將目標價上調至6.88美元。
Morgan Stanley analyst Matthew Harrison upgrades Atea Pharmaceuticals (NASDAQ:AVIR) from Underweight to Equal-Weight and raises the price target from $2 to $6.88.
摩根士丹利分析師Matthew Harrison將Atea Pharmaceuticals（納斯達克代碼：AVIR）的評級由輕倉升級至持平，並將價格目標從2美元提高至6.88美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。